logo
welcome
Reuters

Reuters

Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdles

Reuters
Summary
Nutrition label

81% Informative

Doctors say patients are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and diabetes drugs but cannot always fill them because of supply issues and insurance hurdles.

The medicines' high cost is pushing patients to cheaper compounded versions sold online, doctors, pharmacy officials and Wall Street analysts said.

Lilly last week reported a rare $1.5 billion sales miss for its injectable obesity drug Zepbound and diabetes medicine Mounjaro combined.

VR Score

91

Informative language

96

Neutral language

83

Article tone

formal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links